New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 2, 2014
06:11 EDTBMRNBioMarin says BMN 165-302 study to be available in Q4 of 2015
BioMarin announced last night that it intends to modify the entry criteria for the BMN 165-302 randomized discontinuation study. "The purpose of the eligibility modification is to leverage those patients who have relatively weaker immune reactions to PEG PAL, who therefore achieve Phe reductions faster, at relatively lower doses and with relatively fewer side effects. Under the revised entry criteria, patients will need to demonstrate a pre-specified reduction in blood Phe from PEG PAL during the BMN 165-301 feeder study prior to entering the BMN 165-302 RDT study," it stated. Based on the changed BMN 165-302 protocol, associated review of the proposed protocol and preliminary BMN 165-301 data with the FDA, and requirement for additional patients, the company now expects data from the enriched BMN 165-302 study to be available in Q4 of 2015.
News For BMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 27, 2015
09:44 EDTBMRNBioMarin completes rolling NDA submission to FDA for drisapersen for DMD
Subscribe for More Information
April 21, 2015
14:00 EDTBMRNOptions with decreasing implied volatility
Options with decreasing implied volatility: NFLX MLNX XON WUBA MEMP BMRN FTNT BPT SNDK
April 20, 2015
10:11 EDTBMRNOptions with decreasing implied volatility
Options with decreasing implied volatility: BPT WETF NFLX BMRN SNDK STX TSM MAT FAST INTC
07:18 EDTBMRNAmerican Academy of Neurology to hold annual meeting
Subscribe for More Information
April 17, 2015
10:14 EDTBMRNOptions with decreasing implied volatility
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use